The affected factors of loss to follow up (LFU) among HIV patients with antiretroviral therapy (ART) in Dr. Sardjito General Hospital, Yogyakarta, Indonesia

  • Sri Purwaningsih Dr Sardjito General Hospital, Yogyakarta
  • Yanri Wijayanti Subronto Center for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada Yogyaka
  • Erna Kristin Universitas Gadjah Mada, Indonesia
Keywords: antiretroviral therapy HIV, loss to follow up, CD4, clinical stadium


HIV infection is a global issue which is related to the increasing cases of HIV and AIDS in various countries including in Indonesia. Antiretroviral therapy (ART) that addressed for reducing the virus proliferation is not always followed by good medication adherence among patients. The ART loss to follow up (LFU) is a common problem in Indonesia. However, information concerning the affected factors of LFU among HIV patients with ART is limited. This study aimed to investigate the affected factors of LFU among HIV patients in the early two years of ART. A retrospective cohort study was conducted in Dr. Sardjito General Hospital, Yogyakarta among 369 medical records of HIV patients that met the inclusion and exclusion criteria. The inclusion criteria were HIV patients who started ART in January 2008 to December 2012, aged > 17 years with a complete medical records. The data of sociodemography and medical status patients were obtained from medical record, ART, and pharmacy register of the patients. Patient characteristics observed in this study included demographic factors such as age, sex, residence, education level, risk factors, and also medical status factors such as clinical stage, tuberculosis (TB) co-infection, functional status, and CD4 cell counts. The data were analyzed using Kaplan Meier and Cox Proportional Hazard. The results showed that patients with TB co-infection in early therapy and working functional status were significant factors of LFU (p<0.05). Patients without TB co-infection were half as much protected from LFU compared to patients with TB infection (HR=0.50; 96%CI: 0.34-0.75). It can be concluded that TB coinfection in early therapy and working fuctional status are the significant factors that influenced the LFU incidents in the two years of early therapy.


UNAIDS. UNAIDS Worlds AIDS Day Report 2011, Joint United Nations Programme on HIV/AIDS.2011.

Dinas Kesehatan Prov DIY. 2014. Laporan bulanan HIV tahun 2014.

Kementrian Kesehatan Republik Indonesia (Kemenkes RI). Laporan Perkembangan Situasi HIV dan AIDS di Indonesia triwulan 3 September Tahun 2013. Jakarta: Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, 2013.

Blevins M, Bilhete FR, Vaz LME, Shepherd BE, Audet CM, Vermund SH, et al. Two-year death and loss to follow-up outcomes by source of referral to HIV care for HIV-infected. AIDS Res Hum Retroviruses 2015; 31(2):198–207.

Alvarez-uria G, Naik PK, Pakam R, Midde M. Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India. Glob Health Action 2013; 1:1-8.

Bekolo CE, Webster J, Batenganya M,Sume GE, Kollo B. Trends in mortality and loss to follow-up in HIV care at the Nkongsamba Regional Hospital, Cameroon. BMC Res Notes 2013; 6(1):1–16.

Mugisha V, Teasdale CA, Wang C, Lahuerta M, Biribonwoha HN, Tayebwa E, et al. Determinants of mortality and loss to follow-up among adults enrolled in HIV care services in Rwanda. PloS One 2014; 9(1):e85774.

Schöni-Affolterr F, Keiser O, Mwango A, Stringer J, Mulenga BBL, et al. Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. Plos One 2011; 5(5):e10584.

Gerver SM, Chadborn TR, Ibrahim F, Vatsa B, Delpech VC, Easterbrook PJ, et al. High rate off loss to clinical follow up among African HIV infected patients attending a London clinic; a retrospectif analysis of clinical cohort. J Int AIDS Soc 2010; 13-29.

World Health Organization. Consolidated guidelines on person-centred HIV patient monitoring and case surveillance. Geneva: World Health Organization, 2017.

World Health Organization. Retention in HIV programmes: defining the challenges and identifying solutions: meeting report, 13-15 September 2011. Geneva: World Health Organization, 2012.

Surilena, Minawati, Rensa, Isadora, Suryani E, Hartono TS. Kepatuhan ODHA pengguna NAPZA suntik dengan atau tanpa ko-infeksi TB/Hepatitis virus dalam terapi antiretroviral dan metadon. CDK-230 2015; 42(7):487-92.

Departemen Kesehatan Republik Indonesia. Pedoman nasional perawatan dukungan dan pengobatan bagi ODHA. Jakarta: Direktorat Jendral P2M & PL, 2003.

Hambisa MT, Ali A, Dessie Y. Determinanas of mortality among HIV positives after initiating antiretroviaral therapy in Western Ethiopia: A hospital–based retrospecif cohort study. ISRN AIDS 2013; 2013:491601.

Nansera D, Bajunirwe F, Elyanu P, Asiimwe C, Amanyire G, Graziano F. Mortalty and lossto follow up amnog tuberculosis and HIV co-infection patients in rulal South Western Uganda. Inter J Tuberc Lung Dis 2012; 16(10):1371-76.

Marrone G, Thorson A, Lukhwaro A, Ilako F, Ekstro AM. Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in Sub- Saharan Africa : a prospective cohort study. PloS One 2010; 5(10):e13613.